STOCK TITAN

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags

Ocular Therapeutix (NASDAQ:OCUL), a biopharmaceutical company focused on developing innovative therapies for retinal diseases and other eye conditions, has announced inducement awards for its newly appointed Chief Legal Officer, Todd D.C. Anderman. The awards, granted under Ocular's 2019 Inducement Stock Incentive Plan, include:

1. Non-statutory stock options to purchase up to 296,500 shares of Ocular's common stock at the closing price on October 7, 2024. These options have a ten-year term and vest over four years.

2. Restricted stock unit awards representing 98,700 shares of Ocular's common stock, vesting over three years in equal annual installments.

These inducement equity awards are subject to Mr. Anderman's continued service with Ocular and the terms of the 2019 Inducement Stock Incentive Plan.

Ocular Therapeutix (NASDAQ:OCUL), un'azienda biofarmaceutica focalizzata sullo sviluppo di terapie innovative per le malattie retiniche e altre condizioni oculari, ha annunciato premi di incentivazione per il suo nuovo Chief Legal Officer, Todd D.C. Anderman. I premi, concessi nell'ambito del Piano di Incentivazione Azionaria 2019 di Ocular, includono:

1. Opzioni su azioni non statutarie per l'acquisto di fino a 296.500 azioni ordinarie di Ocular al prezzo di chiusura del 7 ottobre 2024. Queste opzioni hanno una durata di dieci anni e maturano in quattro anni.

2. Premi in azioni limitate che rappresentano 98.700 azioni ordinarie di Ocular, che maturano in tre anni in rate annuali uguali.

Questi premi azionari di incentivazione sono soggetti al continuo servizio del Sig. Anderman con Ocular e ai termini del Piano di Incentivazione Azionaria 2019.

Ocular Therapeutix (NASDAQ:OCUL), una compañía biofarmacéutica centrada en el desarrollo de terapias innovadoras para enfermedades retinianas y otras afecciones oculares, ha anunciado premios de inducimiento para su recién nombrado Director Legal, Todd D.C. Anderman. Los premios, otorgados bajo el Plan de Incentivos de Acciones de Ocular 2019, incluyen:

1. Opciones de acciones no estatutarias para comprar hasta 296,500 acciones ordinarias de Ocular al precio de cierre del 7 de octubre de 2024. Estas opciones tienen un período de diez años y se adquieren en un plazo de cuatro años.

2. Premios de unidades de acciones restringidas que representan 98,700 acciones ordinarias de Ocular, que se adquirirán durante tres años en pagos anuales iguales.

Estos premios de equidad por inducimiento están sujetos al servicio continuo del Sr. Anderman con Ocular y a los términos del Plan de Incentivos de Acciones 2019.

Ocular Therapeutix (NASDAQ:OCUL)은 망막 질환 및 기타 안과 질환에 대한 혁신적인 치료법 개발에 집중하는 생물 의약품 회사로, 새로 임명된 법무 책임자 Todd D.C. Anderman에게 유인 인센티브를 발표했습니다. 이 인센티브는 Ocular의 2019 유인 주식 인센티브 계획에 따라 수여되며, 내용은 다음과 같습니다:

1. 비법적 주식 옵션으로, 최대 296,500주를 2024년 10월 7일 종가로 구매할 수 있습니다. 이 옵션은 10년의 유효기간을 가지며 4년에 걸쳐 배분됩니다.

2. 제한된 주식 단위 보상으로, Ocular의 보통주 98,700주를 대표하며, 3년 동안 매년 동일한 금액으로 배분됩니다.

이 유인 주식 보상은 Anderman 씨의 Ocular에서의 지속적인 서비스 및 2019 유인 주식 인센티브 계획의 조건에 따릅니다.

Ocular Therapeutix (NASDAQ:OCUL), une société biopharmaceutique axée sur le développement de thérapies innovantes pour les maladies rétiniennes et d'autres problèmes oculaires, a annoncé des récompenses d'incitation pour son nouveau directeur juridique, Todd D.C. Anderman. Les récompenses, accordées dans le cadre du Plan d'Incentives d'Actions 2019 d'Ocular, comprennent :

1. Options d'actions non statutaires pour acheter jusqu'à 296 500 actions ordinaires d'Ocular au prix de clôture du 7 octobre 2024. Ces options ont une durée de dix ans et deviennent acquises sur une période de quatre ans.

2. Attributions d'unités d'actions restreintes représentant 98 700 actions ordinaires d'Ocular, qui deviennent acquises sur trois ans en versements annuels égaux.

Ces récompenses d'équité d'incitation sont soumises à la continuité du service de M. Anderman avec Ocular et aux termes du Plan d'Incentives d'Actions 2019.

Ocular Therapeutix (NASDAQ:OCUL), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung innovativer Therapien für Netzhauterkrankungen und andere Augenleiden konzentriert, hat Anreizprämien für seinen neu ernannten Chief Legal Officer, Todd D.C. Anderman, bekannt gegeben. Die Prämien, die im Rahmen des Ocular 2019 Inducement Stock Incentive Plans gewährt werden, umfassen:

1. Nicht-statuarische Aktienoptionen zum Kauf von bis zu 296.500 Aktien der Ocular Stammaktien zum Schlusspreis am 7. Oktober 2024. Diese Optionen haben eine Laufzeit von zehn Jahren und erwerben sich über einen Zeitraum von vier Jahren.

2. Beschränkte Aktien Einheitspreise, die 98.700 Aktien der Ocular Stammaktien repräsentieren und über drei Jahre in gleichen jährlichen Raten ausgrossiert werden.

Diese Anreiz-Aktienvergaben unterliegen der weiteren Dienstleistung von Herrn Anderman bei Ocular und den Bedingungen des 2019 Inducement Stock Incentive Plans.

Positive
  • Appointment of a new Chief Legal Officer, indicating organizational growth
  • Granting of substantial equity awards to attract and retain top talent
Negative
  • Potential dilution of existing shareholders due to the issuance of new stock options and restricted stock units

BEDFORD, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it has agreed to grant inducement awards to its newly appointed Chief Legal Officer, Todd D.C. Anderman. The awards were made as inducements material to Mr. Anderman’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Mr. Anderman’s inducement equity awards were granted effective as of October 7, 2024. Mr. Anderman’s inducement equity awards consist of (i) non-statutory stock options to purchase up to 296,500 shares of Ocular’s common stock at a per share exercise price equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant, and (ii) restricted stock unit awards representing the right to receive 98,700 shares of Ocular’s common stock. The stock option has a ten-year term and is scheduled to vest over four years, with 25% of the original number of shares vesting on the one-year anniversary of the recipient’s employment commencement date and the remainder vesting in equal monthly installments over the three years thereafter, subject to Mr. Anderman’s continued service to Ocular through the applicable vesting dates. The restricted stock unit award is scheduled to vest over three years, in equal annual installments, beginning on October 7, 2024, and subject to his continued service to Ocular through the applicable vesting dates.

The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA ®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.

Follow Ocular on its website, LinkedIn or X.

The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com


FAQ

What inducement awards did Ocular Therapeutix (OCUL) grant to its new Chief Legal Officer?

Ocular Therapeutix granted Todd D.C. Anderman non-statutory stock options to purchase up to 296,500 shares of common stock and restricted stock unit awards representing 98,700 shares of common stock.

When do the stock options granted by Ocular Therapeutix (OCUL) vest?

The stock options vest over four years, with 25% vesting on the one-year anniversary of employment and the remainder vesting in equal monthly installments over the following three years.

How do the restricted stock units granted by Ocular Therapeutix (OCUL) vest?

The restricted stock units vest over three years in equal annual installments, beginning on October 7, 2024.

What is the exercise price for the stock options granted by Ocular Therapeutix (OCUL)?

The exercise price is equal to the closing price of Ocular's common stock on The Nasdaq Global Market on October 7, 2024, the effective date of grant.

Ocular Therapeutix, Inc.

NASDAQ:OCUL

OCUL Rankings

OCUL Latest News

OCUL Stock Data

1.64B
155.92M
1.19%
91.22%
8.51%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BEDFORD